(Q38175443)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24387133%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

title

Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24387133%20AND%20SRC:MED&resulttype=core&format=json

Marco A. Velasco-Velazquez

4 March 2020

author

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24387133%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

4

Richard G Pestell

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24387133%20AND%20SRC:MED&resulttype=core&format=json

Charmina Aguirre-Alvarado

4 March 2020

series ordinal

3

object named as

Charmina Aguirre-Alvarado

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24387133%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

author name string

Mathew C Casimiro

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24387133%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

language of work or name

English

0 references

publication date

3 January 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24387133%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

4 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24387133%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24387133%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24387133%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

page(s)

295-304

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24387133%20AND%20SRC:MED&resulttype=core&format=json

The regulation of protein phosphorylation

4 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Why nature chose phosphate to modify proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

A census of human cancer genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Cell cycle, CDKs and cancer: a changing paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Mammalian cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

G1 phase progression: cycling on cue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

CAK-Cyclin-dependent Activating Kinase: a key kinase in cell cycle control and a target for drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

The role of Cdk7 in CAK function, a retro-retrospective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

The Rb/E2F pathway: expanding roles and emerging paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

The DNA damage response: putting checkpoints in perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Blinded by the Light: The Growing Complexity of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Polar expeditions--provisioning the centrosome for mitosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Centrosome amplification, chromosome instability and cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

A mechanism linking extra centrosomes to chromosomal instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Polo-like kinases (Plks) and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Centrosome maturation: Aurora lights the way to the poles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

The role of nucleophosmin in centrosome duplication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

The decision to enter mitosis: feedback and redundancy in the mitotic entry network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

To cell cycle, swing the APC/C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Secrets of a double agent: CDK7 in cell-cycle control and transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Phosphorylation and functions of the RNA polymerase II CTD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Cracking the RNA polymerase II CTD code

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Cyclin D1 provides a link between development and oncogenesis in the retina and breast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Requirement for cyclin D3 in lymphocyte development and T cell leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Cyclin D3 coordinates the cell cycle during differentiation to regulate erythrocyte size and number

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

21 January 2018

New roles of cyclin D1.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

A novel cyclin encoded by a bcl1-linked candidate oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Molecular pathogenesis and a consequent classification of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele-specific expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

SLUG-induced elevation of D1 cyclin in breast cancer cells through the inhibition of its ubiquitination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

RNAi screen identifies UBE2D3 as a mediator of all-trans retinoic acid-induced cell growth arrest in human acute promyelocytic NB4 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Inhibition of UBE2D3 expression attenuates radiosensitivity of MCF-7 human breast cancer cells by increasing hTERT expression and activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

In vitro ubiquitination of cyclin D1 by ROC1-CUL1 and ROC1-CUL3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Mice lacking cyclin D1 are small and show defects in eye and mammary gland development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Physical interaction of the retinoblastoma protein with human D cyclins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Function of a human cyclin gene as an oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Regulation of retinoblastoma protein functions by ectopic expression of human cyclins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Specific protection against breast cancers by cyclin D1 ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Dissecting the roles of beta-catenin and cyclin D1 during mammary development and neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Cyclin D1 induction of cellular migration requires p27(KIP1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Alternate cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Cyclin D1 kinase activity is required for the self-renewal of mammary stem and progenitor cells that are targets of MMTV-ErbB2 tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

The requirement for cyclin D function in tumor maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Cyclin D1 governs adhesion and motility of macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Fibroblast growth factor-2 induces Lef/Tcf-dependent transcription in human endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Cyclin D1 determines estrogen signaling in the mammary gland in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Tumour-cell invasion and migration: diversity and escape mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Cancer invasion and the microenvironment: plasticity and reciprocity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

New functional activities for the p21 family of CDK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

p21(Cip1) Promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

CDK inhibitors: positive and negative regulators of G1-phase progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

p27Kip1 modulates cell migration through the regulation of RhoA activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Alternative cyclin D1 splice forms differentially regulate the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Chromosomal instability and cancer: a complex relationship with therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Losing balance: the origin and impact of aneuploidy in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Immunodetectable cyclin D(1)is associated with oestrogen receptor but not Ki67 in normal, cancerous and precancerous breast lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Inhibition of cyclin-dependent kinase 1 by purines and pyrrolo[2,3-d]pyrimidines does not correlate with antiviral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Inhibition of cyclin-dependent kinases by purine analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

2,6,8,9-tetrasubstituted purines as new CDK1 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Cell cycle kinases as therapeutic targets for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Whether to target single or multiple CDKs for therapy? That is the question

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

CDK inhibitors in cancer therapy: what is next?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Emerging drug profile: cyclin-dependent kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017

Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.867017